VIEMED HEALTHCARE, INC.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Net income $9.5m $8.5m $31.5m $9.1m $6.2m $10.2m $11.4m $15.4m
Depreciation and amortization $3.8m $6.4m $9.6m $11.3m $15.6m $21.9m $25.4m $28.6m
Amortization of deferred financing costs $0 $0 $187k $228k
Deferred income tax expense (benefit) $0 ($8.7m) $3.9m $1.7m ($1.4m) ($3.8m) $3.1m
Distributions of earnings received from equity method investments $0 $416k $1.1m $980k $147k $0
Income from equity method investments $110k ($91k) ($1.2m) ($935k) ($485k) ($261k) $0
Loss (gain) on disposal of property and equipment $54k $360k ($2.3m) $448k $346k $645k ($1.9m) ($2.2m)
Investment in equity investments $0 ($629k) ($599k) ($141k) ($20k) ($1.0m) $0
Net non-cash changes to operating lease $22.4m $19.1m $35.1m $712k $530k ($41k) $0 $0
Stock-based compensation expense $2.7m $3.9m $4.9m $5.2m $5.2m $5.8m $6.3m $9.1m
Loss (income) from debt investment $0 ($219k) $1.3m $0
Accounts receivable, net ($5.3m) ($12.5m) ($10.0m) ($7.3m) ($12.6m) ($1.1m) ($6.1m) $1.2m
Inventory ($1.3m) ($306k) ($2.3m) ($212k) $301k ($472k) $574k $59k
Prepaid expenses and other assets ($473k) ($623k) ($812k) ($226k) ($2.8m) $2.2m $544k ($503k)
Trade payables $2.5m $783k $213k $133k ($318k) ($859k) $359k $479k
Deferred revenue $807k $725k $94k $344k $871k $851k $364k $359k
Accrued liabilities $3.6m $2.5m $2.3m ($4.0m) $2.5m $5.0m $2.9m $255k
Income tax payable/receivable $10k ($66k) $254k ($2.2m) $1.9m $2.2m $1.7m ($4.1m)
Purchase of property and equipment ($6.1m) ($13.4m) ($13.0m) ($19.7m) ($22.9m) ($26.1m) ($37.8m) ($40.0m)
Cash paid for acquisitions, net of cash acquired $0 ($28.6m) ($3.0m) ($26.3m)
Proceeds from sale of property and equipment $813k $574k $5.3m $596k $1.1m $2.6m $10.3m $16.2m
Proceeds from exercise of options $0 $136k $1.9m $112k $283k $1.3m $1.0m $1.4m
Proceeds from term notes $0 $4.8m $0 $5.0m $0 $9.0m
Principal payments on term notes $0 $67k ($142k) ($152k) ($4.5m) ($3.7m) ($1.1m) ($730k)
Proceeds from revolving credit facilities $0 $8.0m $3.0m $13.0m
Principal payments on revolving credit facilities $0 ($7.0m) ($5.0m) ($13.0m)
Shares redeemed to pay income tax ($1.4m) ($143k) ($594k) ($1.1m) ($1.7m)
Shares repurchased under the share repurchase program ($1.6m) ($1.5m) $0 ($1.4m) ($9.6m) $0 $0 ($13.2m)
Repayments of finance lease liabilities $42k $157k $338k ($50k)
Distributions to non-controlling interest $0 $0 ($36k) ($374k)
Equipment and other fixed asset purchases payable at end of period $6.1m $13.4m $13.0m $19.7m $739k $1.4m $2.2m $3.2m
Equipment sales receivable at end of period $0 $0 $2.8m $0
Non-cash consideration received for sale of debt security $0 $0 $125k $0
Net cash provided by operating activities $22.4m $19.1m $35.1m $22.5m $27.7m $45.2m $39.1m $51.9m
Net cash used in investing activities ($5.3m) ($12.8m) ($8.4m) ($19.7m) ($24.0m) ($52.1m) ($30.7m) ($50.2m)
Proceeds from sale of debt security $0 $0 $750k $0
Payments for debt issuance costs $0 $0 ($192k) ($115k)
Non-cash change in debt from the reclassification of debt issuance costs $0 ($594k) $0 $0
Net cash provided by (used in) financing activities ($11.8m) ($3.3m) ($9.1m) ($5.3m) ($15.3m) $2.8m ($3.7m) ($5.8m)
Net increase (decrease) in cash and cash equivalents $5.3m $2.9m $17.6m ($2.6m) ($11.5m) ($4.1m) $4.7m ($4.0m)
Cash and cash equivalents at beginning of year $10.4m $13.4m $31.0m $28.4m $16.9m $12.8m $17.5m $13.5m
Cash paid during the period for interest $193k $333k $559k $351k $231k $851k $950k $874k
Cash paid during the period for income taxes, net of refunds $151k $338k $3.3m $1.8m ($846k) $3.6m $6.8m $7.4m